Clinical Trial News and Research

RSS

Premature babies who receive interventional therapy plus mother's voice learn to eat efficiently

Premature babies who receive an interventional therapy combining their mother's voice and a pacifier-activated music player learn to eat more efficiently and have their feeding tubes removed sooner than other preemies, according to a Monroe Carell Jr. Children's Hospital at Vanderbilt study published today in Pediatrics.

20 Feb 2014

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

CardioCell LLC announces two new clinical trials using its allogeneic stem-cell therapy to treat subjects with acute myocardial infarction (AMI), a problem facing more than 1.26 million Americans annually.

20 Feb 2014

Medications to lower blood pressure after stroke does not reduce likelihood of death

A major study has found that giving stroke patients medications to lower their blood pressure during the first 48 hours after a stroke does not reduce the likelihood of death or major disability.

20 Feb 2014

Cystinosis Research Foundation granted $2.15M in 2013 to researchers investigating cure for cystinosis

The Cystinosis Research Foundation awarded $2,153,048 in 2013 to researchers investigating better treatments and a cure for cystinosis, a rare metabolic and genetic disease that afflicts about 500 children and young adults in the United States and 2,000 worldwide.

19 Feb 2014

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.

19 Feb 2014

Researchers examine impact of diet for preventing Alzheimer's dementia

A cocktail of ingredients containing omega-3 fatty acid found in fish oil is being tested in patients with mild cognitive impairment as a means to slow the progression of Alzheimer's dementia down

19 Feb 2014

Neuropsychological assessment efficiently tracks disease progression in memory clinic patients

Investigators at the University of Amsterdam, The Netherlands, have shown that progression of disease in memory clinic patients can be tracked efficiently with 45 minutes of neuropsychological testing. MRI measures of brain atrophy were shown to be less reliable to pick up changes in the same patients.

19 Feb 2014

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).

19 Feb 2014

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company's application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer.

19 Feb 2014

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

19 Feb 2014

Matching the right tumor with the right drug

There are three common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. Like a shell game, if you pick the right drug a patient is likely to respond. And, unfortunately, picking the wrong drug can lead to treatment failure. As reported in this month's issue of the journal PLoS ONE, a University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

19 Feb 2014

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

Update Pharma Inc. today announced that the FDA has approved Orphan Drug Status for the use of UPI-928 for the treatment of Acute Myeloid Leukemia (AML).

18 Feb 2014

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

Chelsea Therapeutics International, Ltd. today announced that the U.S. Food and Drug Administration granted accelerated approval of NORTHERA (droxidopa) for the treatment of symptomatic neurogenic orthostatic hypotension (NOH). NORTHERA is the first and only therapy approved by the FDA which demonstrates symptomatic benefit in patients with NOH.

18 Feb 2014

New research points to potential target for treating triple negative breast cancer

New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This provides a potential target for treating triple negative breast cancer, the most aggressive form of the disease.

17 Feb 2014

Commonly-used HIV drug kills HPV that leads to cervical cancer

A commonly-used HIV drug has been shown to kill-off the human papilloma virus (HPV) that leads to cervical cancer in a world-first clinical trial led by The University of Manchester with Kenyatta National Hospital in Nairobi.

17 Feb 2014

Altrient C improves skin firmness and elasticity by 32.7%

...

17 Feb 2014

Highlights: N.D. hospital and abortion docs; Calif. sugary beverage bill; aging home care workers in Texas

A Democratic candidate who has explicitly defended Obamacare holds a slight lead in a special congressional election in Florida that both parties are eyeing as a test of the political impact of the healthcare law. A poll released Thursday by the Tampa Bay Times shows Democrat Alex Sink leading her Republican opponent, David Jolly, 42% to 35% among people considered likely to vote in the March 11 special election.

17 Feb 2014

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Forest Laboratories, Inc., a leading, fully integrated, specialty pharmaceutical company largely focused on the United States market, today announced that it plans to discontinue the sale of NAMENDA (memantine HCl) 5 mg and 10 mg tablets effective August 15, 2014.

16 Feb 2014

Research roundup: Examining readmissions; easing doctor burnout

Despite massive early IT problems, exchange enrollment is accelerating rapidly. While enrollment may not reach 7 million by the end of March, we expect at least 5 million to have enrolled by the close of the initial open-enrollment period. If enrollment falls far short, HHS could extend open enrollment for a fixed period to reach its 7 million target. ... We project that 5 million new beneficiaries will be covered by Medicaid and the Children's Health Insurance Program by the end of 2014. Medicaid managed-care enrollment of non-dual beneficiaries will increase by 20 percent from 2013 to 2014 and by 38 percent from 2013 to 2016. We expect that 75 percent of non-dual Medicaid beneficiaries will be covered by Managed Care Organizations starting in 2015, up from 63 percent in 2012 (Feb. 2014).

14 Feb 2014

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that the National Institute of Allergy and Infectious Diseases has awarded Soligenix a Small Business Innovation Research grant to support further preclinical development of SGX943 as a treatment for melioidosis.

14 Feb 2014

Clinical Trial News and Research

Premature babies who receive interventional therapy plus mother's voice learn to eat efficiently

CardioCell announces new clinical trials using allogeneic stem-cell therapy to treat subjects with AMI

Medications to lower blood pressure after stroke does not reduce likelihood of death

Cystinosis Research Foundation granted $2.15M in 2013 to researchers investigating cure for cystinosis

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Researchers examine impact of diet for preventing Alzheimer's dementia

Neuropsychological assessment efficiently tracks disease progression in memory clinic patients

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

FDA approves CSC’s Phase II clinical trial for cancer immunotherapy in women with ovarian cancer

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

Matching the right tumor with the right drug

Update Pharma's UPI-928 gets FDA orphan drug designation for AML treatment

FDA grants accelerated approval to NORTHERA (droxidopa) for patients with symptomatic NOH

New research points to potential target for treating triple negative breast cancer

Commonly-used HIV drug kills HPV that leads to cervical cancer

Altrient C improves skin firmness and elasticity by 32.7%

Highlights: N.D. hospital and abortion docs; Calif. sugary beverage bill; aging home care workers in Texas

Forest Laboratories plans to discontinue sale of NAMENDA 5 mg and 10 mg tablets

Research roundup: Examining readmissions; easing doctor burnout

NIAID awards Soligenix SBIR grant to further develop SGX943 for treatment of melioidosis

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery